Smith I, Greenside PG, Natoli T, et al. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 2017;15(11):e2003213. doi:10.1371/journal.pbio.2003213.

Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564-576.e16. doi:10.1016/j.cell.2017.06.010.

Xu Y-X, Redon V, Yu H, et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 2018;268:196-206. doi:10.1016/j.atherosclerosis.2017.08.031.

Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem Biol. 2017;24(9):1075-1091. doi:10.1016/j.chembiol.2017.08.002.

Piccioni F, Younger ST, Root DE. Pooled Lentiviral-Delivery Genetic Screens. Curr Protoc Mol Biol. 2018;121:32.1.1-32.1.21. doi:10.1002/cpmb.52.

Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-284. doi:10.1038/nature24049.

Yuan TL, Amzallag A, Bagni R, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018;22(7):1889-1902. doi:10.1016/j.celrep.2018.01.051.

Miller TE, Liau BB, Wallace LC, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017;547(7663):355-359. doi:10.1038/nature23000.

Frank SR, Köllmann CP, Luong P, et al. p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. J Cell Biol. 2018;217(9):3183-3201. doi:10.1083/jcb.201710058.

Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017;114(30):E6147-E6156. doi:10.1073/pnas.1701911114.